Literature DB >> 24670696

Risk factors for treatment default in close contacts with latent tuberculous infection.

C T Fiske1, F-X Yan2, Y Hirsch-Moverman3, T R Sterling1, M R Reichler2.   

Abstract

OBJECTIVE: 1) To characterize risk factors for non-completion of latent tuberculous infection treatment (LTBIT), and 2) to assess the impact of LTBIT regimens on subsequent risk of tuberculosis (TB).
METHODS: Close contacts of adults aged ⩾15 years with pulmonary TB were prospectively enrolled in a multi-center study in the United States and Canada from January 2002 to December 2006. Close contacts of TB patients were screened and cross-matched with TB registries to identify those who developed active TB.
RESULTS: Of 3238 contacts screened, 1714 (53%) were diagnosed with LTBI. Preventive treatment was recommended in 1371 (80%); 1147 (84%) initiated treatment, of whom 723 (63%) completed it. In multivariate analysis, study site, initial interview sites other than a home or health care setting and isoniazid preventive treatment (IPT) were significantly associated with non-completion of LTBIT. Fourteen TB cases were identified in contacts, all of whom initiated IPT: two TB cases among persons who received ⩾6 months of IPT (66 cases/100 000 person-years [py]), and nine among those who received 0-5 months (median 2 months) of IPT (792 cases/100 000 py, P < 0.001); data on duration of IPT were not available for three cases.
CONCLUSION: Only 53% (723/1371) of close contacts for whom IPT was recommended actually completed treatment. Close contacts were significantly less likely to complete LTBIT if they took IPT. Less than 6 months of IPT was associated with increased risk of active TB.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24670696      PMCID: PMC4060979          DOI: 10.5588/ijtld.13.0688

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  30 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

2.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

Authors:  Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

3.  New regimens to prevent tuberculosis in adults with HIV infection.

Authors:  Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

4.  Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil.

Authors:  Valeria Saraceni; Antonio Guilherme Pacheco; Jonathan E Golub; Vitoria Vellozo; Bonnie S King; Solange C Cavalcante; Lois Eldred; Richard E Chaisson; Betina Durovni
Journal:  Braz J Infect Dis       Date:  2011 May-Jun       Impact factor: 1.949

5.  Three months of rifapentine and isoniazid for latent tuberculosis infection.

Authors:  Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

6.  Text messaging for enhancement of testing and treatment for tuberculosis, human immunodeficiency virus, and syphilis: a survey of attitudes toward cellular phones and healthcare.

Authors:  Anna K Person; Michela L M Blain; Helen Jiang; Petra W Rasmussen; Jason E Stout
Journal:  Telemed J E Health       Date:  2011-04-02       Impact factor: 3.536

7.  Human immunodeficiency virus counseling, testing, and referral of close contacts to patients with pulmonary tuberculosis: feasibility and costs.

Authors:  Jiehui Li; Suzanne M Marks; Cynthia R Driver; Francisco A Diaz; Alejandro F Castro; Annette Figueroa de Regner; Aurelia E Gibson; Kinta Dokubo-Okereke; Sonal S Munsiff
Journal:  J Public Health Manag Pract       Date:  2007 May-Jun

8.  Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States.

Authors:  Mary R Reichler; Randall Reves; Sarah Bur; Josie Ford; Virginia Thompson; Bonita Mangura; Ida M Onorato; Sarah E Valway
Journal:  South Med J       Date:  2002-04       Impact factor: 0.954

9.  Evaluation of investigations conducted to detect and prevent transmission of tuberculosis.

Authors:  Mary R Reichler; Randall Reves; Sarah Bur; Virginia Thompson; Bonita T Mangura; Josie Ford; Sarah E Valway; Ida M Onorato
Journal:  JAMA       Date:  2002-02-27       Impact factor: 56.272

10.  Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.

Authors:  Alfred Lardizabal; Marian Passannante; Faysal Kojakali; Christopher Hayden; Lee B Reichman
Journal:  Chest       Date:  2006-12       Impact factor: 9.410

View more
  18 in total

1.  Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons With Infectious Tuberculosis.

Authors:  Mary R Reichler; Awal Khan; Timothy R Sterling; Hui Zhao; Bin Chen; Yan Yuan; Joyce Moran; James McAuley; Bonita Mangura
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

2.  Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.

Authors:  S Swindells; M Siccardi; S E Barrett; D B Olsen; J A Grobler; A T Podany; E Nuermberger; P Kim; C E Barry; A Owen; D Hazuda; C Flexner
Journal:  Int J Tuberc Lung Dis       Date:  2018-02-01       Impact factor: 2.373

3.  One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.

Authors:  Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson
Journal:  N Engl J Med       Date:  2019-03-14       Impact factor: 91.245

4.  Genetic Clustering of Tuberculosis in an Indigenous Community of Brazil.

Authors:  Flávia Patussi Correia Sacchi; Mariana Bento Tatara; Camila Camioli de Lima; Liliane Ferreia da Silva; Eunice Atsuko Cunha; Vera Simonsen; Lucilaine Ferrazoli; Harrison Magdinier Gomes; Sidra Ezidio Gonçalves Vasconcellos; Philip Noel Suffys; Jason R Andrews; Julio Croda
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

5.  Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis.

Authors:  Mary R Reichler; Awal Khan; Timothy R Sterling; Hui Zhao; Joyce Moran; James McAuley; Patricia Bessler; Bonita Mangura
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

6.  Failure to complete treatment for latent tuberculosis infection in Portugal, 2013-2017: geographic-, sociodemographic-, and medical-associated factors.

Authors:  Alexis Sentís; Paula Vasconcelos; Rita Sá Machado; Joan A Caylà; Mònica Guxens; Vasco Peixoto; Raquel Duarte; Isabel Carvalho; Carlos Carvalho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-03       Impact factor: 3.267

7.  An evaluation of tuberculosis contact investigations against national standards.

Authors:  Sean M Cavany; Tom Sumner; Emilia Vynnycky; Clare Flach; Richard G White; H Lucy Thomas; Helen Maguire; Charlotte Anderson
Journal:  Thorax       Date:  2017-04-07       Impact factor: 9.139

8.  Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection.

Authors:  Mary R Reichler; Awal Khan; Yan Yuan; Bin Chen; James McAuley; Bonita Mangura; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

9.  Combined Analysis of IFN-γ, IL-2, IL-5, IL-10, IL-1RA and MCP-1 in QFT Supernatant Is Useful for Distinguishing Active Tuberculosis from Latent Infection.

Authors:  Maho Suzukawa; Shunsuke Akashi; Hideaki Nagai; Hiroyuki Nagase; Hiroyuki Nakamura; Hirotoshi Matsui; Akira Hebisawa; Ken Ohta
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240

10.  Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.

Authors:  D Thindwa; P MacPherson; A T Choko; M Khundi; R Sambakunsi; L G Ngwira; T Kalua; E L Webb; E L Corbett
Journal:  Int J Tuberc Lung Dis       Date:  2018-03-01       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.